###begin article-title 0
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
###end article-title 0
###begin p 1
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Background</italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 514 519 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 539 550 539 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methodology</italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1073 1078 1073 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1098 1105 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Results</italic>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1306 1311 1303 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1387 1391 1384 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF1</italic>
###xml 1396 1401 1393 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2</italic>
###xml 1451 1456 1448 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1477 1478 1474 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1489 1501 1486 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Significance</italic>
###xml 1501 1506 1498 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1664 1670 1658 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2-</italic>
###xml 636 641 <span type="species:ncbi:9606">human</span>
BackgroundBRCA1- and BRCA2-associated tumors appear to have distinct molecular signatures. BRCA1-associated tumors are predominantly basal-like cancers, whereas BRCA2-associated tumors have a predominant luminal-like phenotype. These two molecular signatures reflect in part the two cell types found in the terminal duct lobular unit of the breast. To elucidate novel genes involved in these two spectra of breast tumorigenesis we performed global gene expression analysis on breast tumors from germline BRCA1 and BRCA2 mutation carriers. Methodology Breast tumor RNAs from 7 BRCA1 and 6 BRCA2 mutation carriers were profiled using UHN human 19K cDNA microarrays. Supervised univariate analyses were conducted to identify genes differentially expressed between BRCA1 and BRCA2-associated tumors. Selected discriminatory genes were validated using real time reverse transcription polymerase chain reaction in the tumor RNAs, and/or by immunohistochemistry (IHC) or by in situ hybridization (ISH) on tissue microarrays (TMAs) containing an independent set of 58 BRCA1 and 64 BRCA2-associated tumors. Results Genes more highly expressed in BRCA1-associated tumors included stathmin, osteopontin, TGFbeta2 and Jagged 1 in addition to genes previously identified as characteristic of basal-like breast cancers. BRCA2-associated cancers were characterized by the higher relative expression of FGF1 and FGFR2. FGFR2 protein was also more highly expressed in BRCA2-associated cancers (P = 0.004). SignificanceBRCA1-associated tumours demonstrated increased expression of component genes of the Notch and TGFbeta pathways whereas the higher expression of FGFR2 and FGF1 in BRCA2-associated cancers suggests the existence of an autocrine stimulatory loop.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s10549-008-0087-1) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
BRCA1- and BRCA2-associated tumors have many morphologic features in common. These include ductal histology, high histologic grade, pushing tumor margins and a notable host lymphocytic response [1, 2]. Despite these similarities they have distinct molecular signatures; BRCA1-associated tumors have been shown to be predominantly estrogen receptor negative and to have a basal phenotype [3-5], whereas we have shown previously that BRCA2-associated tumors have a luminal phenotype characterized by the expression of estrogen receptor and luminal-type cytokeratins [1]. These two molecular signatures reflect in part the two cell types, basal/myoepithelial and luminal found in the terminal duct lobular unit of the normal breast.
###end p 6
###begin p 7
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 363 368 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 11 16 <span type="species:ncbi:9606">human</span>
Basal-like human breast cancers have been shown to exhibit aberrations in the epidermal growth factor receptor (EGFR) signaling pathway [6]. With the exception of Cyclin D1, genes responsible for promoting the growth and survival of BRCA2-associated cancers have yet to be identified [7]. Our objective in performing global gene expression analysis on BRCA1- and BRCA2-associated tumors was to distinguish these distinct pathways of carcinogenesis and to elucidate novel genes necessary for the transformation and survival of BRCA2-associated tumors.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Breast cancer cases
###end title 9
###begin p 10
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
Flash frozen tumor tissue was available from 7 germline BRCA1 carriers and 6 germline BRCA2 carriers participating in the Ontario Familial Breast Cancer Registry (OFBCR) [8, 9] and the Ontario Cancer Genetics Network (OCGN). Following pathologic confirmation of invasive disease, the tumor tissue was frozen and stored in liquid nitrogen. Testing for germline mutations in BRCA1 and BRCA2 was performed using an RNA/DNA-based protein truncation test with complementary 5' sequencing as previously described [10]. All mutations were confirmed by DNA sequencing. Mutations were classified as deleterious if they were protein-truncating, missense mutations (rare), or splice-site mutations as defined by the Breast Informatics Consortium ().
###end p 10
###begin p 11
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 498 505 498 505 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 553 558 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 505 584 505 584 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12">Clinicopathologic characteristics of <italic>BRCA1</italic>- and <italic>BRCA2</italic>-associated breast cancers</p>
###xml 505 584 505 584 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="12">Clinicopathologic characteristics of <italic>BRCA1</italic>- and <italic>BRCA2</italic>-associated breast cancers</p></caption>
###xml 590 591 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 584 591 584 591 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">LAB ID<sup>a</sup></th>
###xml 591 599 591 599 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mutation</th>
###xml 599 622 599 622 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Type of invasive cancer</th>
###xml 622 638 622 638 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age at diagnosis</th>
###xml 638 643 638 643 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Grade</th>
###xml 643 661 643 661 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lymphatic invasion</th>
###xml 661 682 661 682 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Blood vessel invasion</th>
###xml 684 685 684 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 682 685 682 685 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ER<sup>b</sup></th>
###xml 687 688 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 685 688 685 688 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR<sup>c</sup></th>
###xml 584 688 584 688 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">LAB ID<sup>a</sup></th><th align="left">Mutation</th><th align="left">Type of invasive cancer</th><th align="left">Age at diagnosis</th><th align="left">Grade</th><th align="left">Lymphatic invasion</th><th align="left">Blood vessel invasion</th><th align="left">ER<sup>b</sup></th><th align="left">PR<sup>c</sup></th></tr>
###xml 584 688 584 688 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">LAB ID<sup>a</sup></th><th align="left">Mutation</th><th align="left">Type of invasive cancer</th><th align="left">Age at diagnosis</th><th align="left">Grade</th><th align="left">Lymphatic invasion</th><th align="left">Blood vessel invasion</th><th align="left">ER<sup>b</sup></th><th align="left">PR<sup>c</sup></th></tr></thead>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 688 702 688 702 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="9"><italic>BRCA1</italic> mutation</td>
###xml 688 702 688 702 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="9"><italic>BRCA1</italic> mutation</td></tr>
###xml 702 706 702 706 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3435</td>
###xml 706 713 706 713 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2457C-T</td>
###xml 724 725 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 713 725 713 725 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST<sup>d</sup></td>
###xml 725 727 725 727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">50</td>
###xml 727 728 727 728 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 728 734 728 734 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 734 740 734 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 743 744 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 740 744 740 744 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg<sup>e</sup></td>
###xml 744 747 744 747 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 702 747 702 747 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3435</td><td align="left">2457C-T</td><td align="left">Ductal, NST<sup>d</sup></td><td align="left">50</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Neg<sup>e</sup></td><td align="left">Neg</td></tr>
###xml 747 751 747 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4080</td>
###xml 751 759 751 759 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">185delAG</td>
###xml 759 770 759 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 770 772 770 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">40</td>
###xml 772 773 772 773 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 773 779 773 779 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 779 785 779 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 788 789 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 785 789 785 789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Equ<sup>f</sup></td>
###xml 792 793 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
###xml 789 793 789 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos<sup>g</sup></td>
###xml 747 793 747 793 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4080</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">40</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ<sup>f</sup></td><td align="left">Pos<sup>g</sup></td></tr>
###xml 793 797 793 797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4326</td>
###xml 797 805 797 805 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">185delAG</td>
###xml 805 816 805 816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 816 818 816 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">35</td>
###xml 818 819 818 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 819 825 819 825 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 825 831 825 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 833 834 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">h</sup>
###xml 831 834 831 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA<sup>h</sup></td>
###xml 834 837 834 837 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 793 837 793 837 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4326</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">35</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">NA<sup>h</sup></td><td align="left">Neg</td></tr>
###xml 837 841 837 841 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1834</td>
###xml 841 852 841 852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5293delAAAG</td>
###xml 852 863 852 863 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 863 865 863 865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30</td>
###xml 865 866 865 866 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 866 873 866 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 873 879 873 879 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 879 882 879 882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 882 884 882 884 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 837 884 837 884 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1834</td><td align="left">5293delAAAG</td><td align="left">Ductal, NST</td><td align="left">30</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">NA</td></tr>
###xml 884 888 884 888 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1693</td>
###xml 888 896 888 896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5382insC</td>
###xml 896 907 896 907 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 907 909 907 909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">44</td>
###xml 909 910 909 910 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 910 916 910 916 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 916 922 916 922 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 922 925 922 925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Equ</td>
###xml 925 928 925 928 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 884 928 884 928 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1693</td><td align="left">5382insC</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ</td><td align="left">Pos</td></tr>
###xml 928 932 928 932 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2528</td>
###xml 932 939 932 939 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4603G-T</td>
###xml 939 950 939 950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 950 952 950 952 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33</td>
###xml 952 953 952 953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 953 955 953 955 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 955 957 955 957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 957 960 957 960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 960 963 960 963 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 928 963 928 963 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2528</td><td align="left">4603G-T</td><td align="left">Ductal, NST</td><td align="left">33</td><td align="left">3</td><td align="left">NA</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Pos</td></tr>
###xml 963 967 963 967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3078</td>
###xml 967 975 967 975 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">185delAG</td>
###xml 975 986 975 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 986 988 986 988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">32</td>
###xml 988 989 988 989 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 989 996 989 996 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 996 1003 996 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1003 1006 1003 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1006 1009 1006 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Equ</td>
###xml 963 1009 963 1009 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3078</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">32</td><td align="left">3</td><td align="left">Present</td><td align="left">Present</td><td align="left">Neg</td><td align="left">Equ</td></tr>
###xml 1009 1014 1009 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1009 1023 1009 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="9"><italic>BRCA2</italic> mutation</td>
###xml 1009 1023 1009 1023 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="9"><italic>BRCA2</italic> mutation</td></tr>
###xml 1023 1027 1023 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4324</td>
###xml 1027 1036 1027 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8765delAG</td>
###xml 1036 1047 1036 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1047 1049 1047 1049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">44</td>
###xml 1049 1050 1049 1050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1050 1057 1050 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1057 1063 1057 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 1063 1066 1063 1066 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1066 1069 1066 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1023 1069 1023 1069 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4324</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Pos</td></tr>
###xml 1069 1073 1069 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4472</td>
###xml 1073 1086 1073 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IVS16&#160;+&#160;3 A-C</td>
###xml 1086 1097 1086 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1097 1099 1097 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">44</td>
###xml 1099 1100 1099 1100 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1100 1106 1100 1106 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 1106 1108 1106 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1108 1111 1108 1111 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1111 1114 1111 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1069 1114 1069 1114 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4472</td><td align="left">IVS16&#160;+&#160;3 A-C</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Neg</td></tr>
###xml 1114 1118 1114 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2172</td>
###xml 1118 1126 1118 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6174delT</td>
###xml 1126 1137 1126 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1137 1139 1137 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">46</td>
###xml 1139 1140 1139 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1140 1147 1140 1147 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1147 1149 1147 1149 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 1149 1152 1149 1152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1152 1155 1152 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1114 1155 1114 1155 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2172</td><td align="left">6174delT</td><td align="left">Ductal, NST</td><td align="left">46</td><td align="left">3</td><td align="left">Present</td><td align="left">NA</td><td align="left">Pos</td><td align="left">Pos</td></tr>
###xml 1155 1159 1155 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3627</td>
###xml 1159 1167 1159 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9132delC</td>
###xml 1167 1178 1167 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1178 1180 1178 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">34</td>
###xml 1180 1181 1180 1181 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1181 1188 1181 1188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1188 1194 1188 1194 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 1194 1197 1194 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1197 1200 1197 1200 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1155 1200 1155 1200 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3627</td><td align="left">9132delC</td><td align="left">Ductal, NST</td><td align="left">34</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Pos</td></tr>
###xml 1200 1204 1200 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4374</td>
###xml 1204 1213 1204 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8765delAG</td>
###xml 1213 1224 1213 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1224 1226 1224 1226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">58</td>
###xml 1226 1227 1226 1227 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1227 1234 1227 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1234 1240 1234 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 1240 1243 1240 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1243 1246 1243 1246 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Neg</td>
###xml 1200 1246 1200 1246 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4374</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">58</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Neg</td></tr>
###xml 1246 1250 1246 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3242</td>
###xml 1250 1258 1250 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6764insA</td>
###xml 1258 1269 1258 1269 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ductal, NST</td>
###xml 1269 1271 1269 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">75</td>
###xml 1271 1272 1271 1272 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1272 1279 1272 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Present</td>
###xml 1279 1285 1279 1285 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Absent</td>
###xml 1285 1288 1285 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pos</td>
###xml 1288 1291 1288 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Equ</td>
###xml 1246 1291 1246 1291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3242</td><td align="left">6764insA</td><td align="left">Ductal, NST</td><td align="left">75</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Equ</td></tr>
###xml 688 1291 688 1291 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="9"><italic>BRCA1</italic> mutation</td></tr><tr><td align="left">3435</td><td align="left">2457C-T</td><td align="left">Ductal, NST<sup>d</sup></td><td align="left">50</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Neg<sup>e</sup></td><td align="left">Neg</td></tr><tr><td align="left">4080</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">40</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ<sup>f</sup></td><td align="left">Pos<sup>g</sup></td></tr><tr><td align="left">4326</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">35</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">NA<sup>h</sup></td><td align="left">Neg</td></tr><tr><td align="left">1834</td><td align="left">5293delAAAG</td><td align="left">Ductal, NST</td><td align="left">30</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">NA</td></tr><tr><td align="left">1693</td><td align="left">5382insC</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ</td><td align="left">Pos</td></tr><tr><td align="left">2528</td><td align="left">4603G-T</td><td align="left">Ductal, NST</td><td align="left">33</td><td align="left">3</td><td align="left">NA</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">3078</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">32</td><td align="left">3</td><td align="left">Present</td><td align="left">Present</td><td align="left">Neg</td><td align="left">Equ</td></tr><tr><td align="left" colspan="9"><italic>BRCA2</italic> mutation</td></tr><tr><td align="left">4324</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">4472</td><td align="left">IVS16&#160;+&#160;3 A-C</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">2172</td><td align="left">6174delT</td><td align="left">Ductal, NST</td><td align="left">46</td><td align="left">3</td><td align="left">Present</td><td align="left">NA</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">3627</td><td align="left">9132delC</td><td align="left">Ductal, NST</td><td align="left">34</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">4374</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">58</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">3242</td><td align="left">6764insA</td><td align="left">Ductal, NST</td><td align="left">75</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Equ</td></tr></tbody>
###xml 584 1291 584 1291 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">LAB ID<sup>a</sup></th><th align="left">Mutation</th><th align="left">Type of invasive cancer</th><th align="left">Age at diagnosis</th><th align="left">Grade</th><th align="left">Lymphatic invasion</th><th align="left">Blood vessel invasion</th><th align="left">ER<sup>b</sup></th><th align="left">PR<sup>c</sup></th></tr></thead><tbody><tr><td align="left" colspan="9"><italic>BRCA1</italic> mutation</td></tr><tr><td align="left">3435</td><td align="left">2457C-T</td><td align="left">Ductal, NST<sup>d</sup></td><td align="left">50</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Neg<sup>e</sup></td><td align="left">Neg</td></tr><tr><td align="left">4080</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">40</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ<sup>f</sup></td><td align="left">Pos<sup>g</sup></td></tr><tr><td align="left">4326</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">35</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">NA<sup>h</sup></td><td align="left">Neg</td></tr><tr><td align="left">1834</td><td align="left">5293delAAAG</td><td align="left">Ductal, NST</td><td align="left">30</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">NA</td></tr><tr><td align="left">1693</td><td align="left">5382insC</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ</td><td align="left">Pos</td></tr><tr><td align="left">2528</td><td align="left">4603G-T</td><td align="left">Ductal, NST</td><td align="left">33</td><td align="left">3</td><td align="left">NA</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">3078</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">32</td><td align="left">3</td><td align="left">Present</td><td align="left">Present</td><td align="left">Neg</td><td align="left">Equ</td></tr><tr><td align="left" colspan="9"><italic>BRCA2</italic> mutation</td></tr><tr><td align="left">4324</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">4472</td><td align="left">IVS16&#160;+&#160;3 A-C</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">2172</td><td align="left">6174delT</td><td align="left">Ductal, NST</td><td align="left">46</td><td align="left">3</td><td align="left">Present</td><td align="left">NA</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">3627</td><td align="left">9132delC</td><td align="left">Ductal, NST</td><td align="left">34</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">4374</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">58</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">3242</td><td align="left">6764insA</td><td align="left">Ductal, NST</td><td align="left">75</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Equ</td></tr></tbody></table>
###xml 1291 1292 1291 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1291 1317 1291 1317 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13"><sup>a</sup>ID: Identification number</p>
###xml 1317 1318 1317 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1317 1339 1317 1339 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="14"><sup>b</sup>ER: Estrogen receptor</p>
###xml 1339 1340 1339 1340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1339 1365 1339 1365 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15"><sup>c</sup>PR: Progesterone receptor</p>
###xml 1365 1366 1365 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1365 1386 1365 1386 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16"><sup>d</sup>NST: No special type</p>
###xml 1386 1387 1386 1387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 1386 1400 1386 1400 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17"><sup>e</sup>Neg: Negative</p>
###xml 1400 1401 1400 1401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 1400 1416 1400 1416 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><sup>f</sup>Equ: Equivalent</p>
###xml 1416 1417 1416 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
###xml 1416 1430 1416 1430 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19"><sup>g</sup>Pos: Positive</p>
###xml 1430 1431 1430 1431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">h</sup>
###xml 1430 1448 1430 1448 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20"><sup>h</sup>NA: Not available</p>
###xml 1291 1448 1291 1448 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="13"><sup>a</sup>ID: Identification number</p><p textid="14"><sup>b</sup>ER: Estrogen receptor</p><p textid="15"><sup>c</sup>PR: Progesterone receptor</p><p textid="16"><sup>d</sup>NST: No special type</p><p textid="17"><sup>e</sup>Neg: Negative</p><p textid="18"><sup>f</sup>Equ: Equivalent</p><p textid="19"><sup>g</sup>Pos: Positive</p><p textid="20"><sup>h</sup>NA: Not available</p></table-wrap-foot>
###xml 498 1448 498 1448 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="12">Clinicopathologic characteristics of <italic>BRCA1</italic>- and <italic>BRCA2</italic>-associated breast cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">LAB ID<sup>a</sup></th><th align="left">Mutation</th><th align="left">Type of invasive cancer</th><th align="left">Age at diagnosis</th><th align="left">Grade</th><th align="left">Lymphatic invasion</th><th align="left">Blood vessel invasion</th><th align="left">ER<sup>b</sup></th><th align="left">PR<sup>c</sup></th></tr></thead><tbody><tr><td align="left" colspan="9"><italic>BRCA1</italic> mutation</td></tr><tr><td align="left">3435</td><td align="left">2457C-T</td><td align="left">Ductal, NST<sup>d</sup></td><td align="left">50</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Neg<sup>e</sup></td><td align="left">Neg</td></tr><tr><td align="left">4080</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">40</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ<sup>f</sup></td><td align="left">Pos<sup>g</sup></td></tr><tr><td align="left">4326</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">35</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">NA<sup>h</sup></td><td align="left">Neg</td></tr><tr><td align="left">1834</td><td align="left">5293delAAAG</td><td align="left">Ductal, NST</td><td align="left">30</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">NA</td></tr><tr><td align="left">1693</td><td align="left">5382insC</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">Absent</td><td align="left">Equ</td><td align="left">Pos</td></tr><tr><td align="left">2528</td><td align="left">4603G-T</td><td align="left">Ductal, NST</td><td align="left">33</td><td align="left">3</td><td align="left">NA</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">3078</td><td align="left">185delAG</td><td align="left">Ductal, NST</td><td align="left">32</td><td align="left">3</td><td align="left">Present</td><td align="left">Present</td><td align="left">Neg</td><td align="left">Equ</td></tr><tr><td align="left" colspan="9"><italic>BRCA2</italic> mutation</td></tr><tr><td align="left">4324</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Pos</td></tr><tr><td align="left">4472</td><td align="left">IVS16&#160;+&#160;3 A-C</td><td align="left">Ductal, NST</td><td align="left">44</td><td align="left">3</td><td align="left">Absent</td><td align="left">NA</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">2172</td><td align="left">6174delT</td><td align="left">Ductal, NST</td><td align="left">46</td><td align="left">3</td><td align="left">Present</td><td align="left">NA</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">3627</td><td align="left">9132delC</td><td align="left">Ductal, NST</td><td align="left">34</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Pos</td></tr><tr><td align="left">4374</td><td align="left">8765delAG</td><td align="left">Ductal, NST</td><td align="left">58</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Neg</td><td align="left">Neg</td></tr><tr><td align="left">3242</td><td align="left">6764insA</td><td align="left">Ductal, NST</td><td align="left">75</td><td align="left">3</td><td align="left">Present</td><td align="left">Absent</td><td align="left">Pos</td><td align="left">Equ</td></tr></tbody></table><table-wrap-foot><p textid="13"><sup>a</sup>ID: Identification number</p><p textid="14"><sup>b</sup>ER: Estrogen receptor</p><p textid="15"><sup>c</sup>PR: Progesterone receptor</p><p textid="16"><sup>d</sup>NST: No special type</p><p textid="17"><sup>e</sup>Neg: Negative</p><p textid="18"><sup>f</sup>Equ: Equivalent</p><p textid="19"><sup>g</sup>Pos: Positive</p><p textid="20"><sup>h</sup>NA: Not available</p></table-wrap-foot></table-wrap>
###xml 402 414 <span type="species:ncbi:9606">participants</span>
The clinicopathologic characteristics and mutation status (for the BRCA1-associated and BRCA2-associated tumors) are summarized in Table 1. Tumors were classified according to the WHO histologic classification of breast tumors [11] and graded by central pathology review using the Nottingham histologic grading system [12]. The pathologist was blinded to the mutational status or family history of the participants. Receptor status was obtained by either biochemical or immunohistochemical methods.Table 1Clinicopathologic characteristics of BRCA1- and BRCA2-associated breast cancersLAB IDaMutationType of invasive cancerAge at diagnosisGradeLymphatic invasionBlood vessel invasionERbPRcBRCA1 mutation34352457C-TDuctal, NSTd503AbsentAbsentNegeNeg4080185delAGDuctal, NST403AbsentAbsentEqufPosg4326185delAGDuctal, NST353AbsentAbsentNAhNeg18345293delAAAGDuctal, NST303PresentAbsentNegNA16935382insCDuctal, NST443AbsentAbsentEquPos25284603G-TDuctal, NST333NANANegPos3078185delAGDuctal, NST323PresentPresentNegEquBRCA2 mutation43248765delAGDuctal, NST443PresentAbsentNegPos4472IVS16 + 3 A-CDuctal, NST443AbsentNANegNeg21726174delTDuctal, NST463PresentNAPosPos36279132delCDuctal, NST343PresentAbsentPosPos43748765delAGDuctal, NST583PresentAbsentNegNeg32426764insADuctal, NST753PresentAbsentPosEquaID: Identification numberbER: Estrogen receptorcPR: Progesterone receptordNST: No special typeeNeg: NegativefEqu: EquivalentgPos: PositivehNA: Not available
###end p 11
###begin p 12
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Clinicopathologic characteristics of BRCA1- and BRCA2-associated breast cancers
###end p 12
###begin p 13
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aID: Identification number
###end p 13
###begin p 14
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bER: Estrogen receptor
###end p 14
###begin p 15
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cPR: Progesterone receptor
###end p 15
###begin p 16
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dNST: No special type
###end p 16
###begin p 17
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
eNeg: Negative
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
fEqu: Equivalent
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
gPos: Positive
###end p 19
###begin p 20
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">h</sup>
hNA: Not available
###end p 20
###begin p 21
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
A validation set of formalin-fixed paraffin-embedded (FFPE) tumors from 58 BRCA1 carriers, 64 BRCA2 carriers and 242 additional individuals from the OFBCR without BRCA1 or BRCA2 mutations was used to construct tissue microarrays (TMAs).
###end p 21
###begin title 22
RNA extraction and reverse transcription
###end title 22
###begin p 23
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
Total RNA was isolated from 20 to 50 mg of tumor tissue using TRIzol reagent (Gibco BRL Life Technologies). Reference RNA was a pool of 13 cell lines, modified from the common reference cell line list [13]. Tumor and reference RNAs (5 mug) were reverse transcribed with Superscript III reverse transcriptase (Invitrogen) to yield cDNA. Tumor and reference cDNA (5 mug) were indirectly labeled using aminoallyl nucleotide analogs with Cy3 and Cy5 fluorescent tags, respectively.
###end p 23
###begin title 24
Dye labeling and cDNA array hybridisation
###end title 24
###begin p 25
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
The labeled probes were simultaneously hybridized to UHN human 19K cDNA microarray slides (), and incubated overnight at 42degreesC. These 19K cDNA microarrays are single-spotted and contain 19,008 characterized or unknown human expressed sequence tags (ESTs). The clone set has been sequence-verified at the UHN Microarray Centre, Toronto. Following hybridization the slides were washed and scanned using an Axon scanner. Fluorescent dye swap experiments were also performed for two tumors.
###end p 25
###begin title 26
Pre-processing of expression data
###end title 26
###begin p 27
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
The gene expression data were obtained from the original image files as spot intensities by correcting the mean foreground for each spot with the median local background. The array quality was controlled by requiring arrays to have more than 80% of spots with spot intensities higher than their local background and more than 75% of spots with spot intensity higher than 1.2 times their local background in both channels [14]. Spots with foreground intensity lower than background were treated as missing. A relative expression value was obtained for each gene as the log base 2 ratio of the adjusted intensity for the sample channel versus the reference channel. The log2 ratios were normalized by a within-subarray print-tip "loess" adjustment, followed by a between-array scale adjustment [15]. Poor quality spots as flagged by the GenePix image analysis software were excluded from the normalization. Pre-processing and normalization were carried out using the R-Bioconductor package LIMMA [16]; ). There were 18,981 genes retained in the final data set for analysis.
###end p 27
###begin title 28
###xml 6 9 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
TaqMan(R) assay-based real-time RT-PCR
###end title 28
###begin p 29
###xml 295 298 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
mRNA expression levels of six selected genes that were statistically significantly differentially expressed between the two tumor groups and/or of biologic interest were measured in representative tumor specimens by real-time reverse transcription-polymerase chain reaction (RT-PCR) using TaqMan(R) PRISM 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Gene expression levels were determined by quantification relative to a control gene, hypoxanthine guanine phosphorbosyl transferase (HPRT). cDNA was generated using the ABI High Capacity cDNA Archiving Kit (Applied Biosystems, Foster City, CA) and RT-PCR reactions were carried out following the manufacturer's protocol.
###end p 29
###begin title 30
Tissue microarrays
###end title 30
###begin p 31
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 467 469 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Tissue microarrays were constructed as previously described [1] using FFPE tumors from 58 BRCA1 carriers, 64 BRCA2 carriers and 242 individuals without BRCA1 or BRCA2 mutations from the OFBCR. 4 mum thick sections of these blocks were used for immunohistochemical staining with the FGFR2 antibody (polyclonal, Abcam). 5 mum thick sections were used for mRNA in situ hybridization (ISH). ISH analysis of breast cancer has been reported in detail elsewhere previously [17]. Briefly, a cDNA probe for ISH was made to the gene of interest using 33P-UTP-radiolabeled cRNA. Using routine techniques the TMA sections were hybridized with the radiolabeled antisense probe, washed, and treated with Kodak NBT-2 nuclear emulsion. The sections from the TMAs were stored at 4degreesC for several weeks prior to development in Kodak D-19 solution; they were subsequently fixed in Kodafix and counterstained with 0.1% toludine blue.
###end p 31
###begin p 32
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Immunoreactivity and mRNA ISH was scored using the Allred method [18], which combined the intensity of staining with the percentage of positive tumor cells observable resulting in a combined score of 0-8. For FGFR2, a score of 7 or above was considered positive; for Jagged 1, a previously determined score of 4 or higher [17] was considered positive.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 535 540 535 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 645 646 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 697 698 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 705 706 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
To identify genes that discriminate between BRCA1- and BRCA2-associated tumors, supervised univariate analyses of array-based log2 gene expression were performed for each clone treating the modified Student t-test as the primary analysis [19] using the SAM procedure implemented in open source software, version 2.1.0 (). To assess the sensitivity of the results to this analysis method the random variance test was also applied using BRB ArrayTools (). For each test, all clones were ranked according to their ability to discriminate BRCA1-associated tumors from BRCA2-associated tumors. Supplementary Table 1 reports discriminating genes with P-values </= 0.01 according to the modified Student t-test. P-values were not adjusted for multiple testing.
###end p 34
###begin p 35
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Log2 transformed relative expression of genes validated by RT-PCR was compared to array-based log2 gene expression via scatter plots. Means of the RT-PCR expressions were compared between the two BRCA tumor groups using the Student's t-test and Welch unequal variance t-tests. All tests were two-sided. P-values were not adjusted for multiple testing.
###end p 35
###begin p 36
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The proportion of tumors positive by immunohistochemical staining and mRNA ISH for BRCA1-associated and BRCA2-associated tumors were compared using Fisher's exact test for association. All tests were two sided. Statistical analysis was performed using SAS 9.1 software (SAS, Institute Inc., Cary, North Carolina). P-values were not adjusted for multiple testing.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Clinicopathologic characteristics of BRCA1- and BRCA2-associated tumors
###end title 38
###begin p 39
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
Thirteen tumors were obtained from individuals known to harbor a BRCA1 or BRCA2 germline mutation. As indicated in Table 1, all of the 13 BRCA-associated tumors were grade III/III invasive ductal, no special type tumors (NST). Both ER positive/equivalent and negative tumors were included among the BRCA1 and BRCA2 carriers. The mean age at diagnosis of the BRCA1 patients was somewhat younger than the mean age for the BRCA2 subjects (38 vs. 43 years).
###end p 39
###begin title 40
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Identification of genes that distinguish BRCA1- and BRCA2-associated breast tumors
###end title 40
###begin p 41
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 403 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 404 410 402 408 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 461 467 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-</italic>
###xml 484 489 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 684 685 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 410 851 408 849 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Unsupervised two dimensional cluster analysis of 7 <italic>BRCA1-</italic>associated and 6 <italic>BRCA2</italic>-associated breast tumors. Two dimensional presentation of transcript ratios for 13 tumors. The top 150 significant genes differentially expressed between the two tumor groups from SAM Moderated <italic>t</italic>-test are shown. Each column represents a tumor and each row a gene. As shown in the color bar, red indicates up regulation, green down regulation and black no change</p>
###xml 410 851 408 849 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Unsupervised two dimensional cluster analysis of 7 <italic>BRCA1-</italic>associated and 6 <italic>BRCA2</italic>-associated breast tumors. Two dimensional presentation of transcript ratios for 13 tumors. The top 150 significant genes differentially expressed between the two tumor groups from SAM Moderated <italic>t</italic>-test are shown. Each column represents a tumor and each row a gene. As shown in the color bar, red indicates up regulation, green down regulation and black no change</p></caption>
###xml 851 851 849 849 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2008_87_Fig1_HTML" id="MO1"/>
###xml 404 851 402 849 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="42">Unsupervised two dimensional cluster analysis of 7 <italic>BRCA1-</italic>associated and 6 <italic>BRCA2</italic>-associated breast tumors. Two dimensional presentation of transcript ratios for 13 tumors. The top 150 significant genes differentially expressed between the two tumor groups from SAM Moderated <italic>t</italic>-test are shown. Each column represents a tumor and each row a gene. As shown in the color bar, red indicates up regulation, green down regulation and black no change</p></caption><graphic position="anchor" xlink:href="10549_2008_87_Fig1_HTML" id="MO1"/></fig>
The modified Student t-test was used to identify clones on the arrays that were differentially expressed between the BRCA1- and BRCA2-associated breast tumors. There were 4 distinguishing clones with a P-value < 0.001 and 127 clones with a P-value < 0.01. The 150 top-ranked differentially expressed genes with a P-value of </=0.01 are listed in supplementary Table 1 and displayed as a heat map, Fig. 1.Fig. 1Unsupervised two dimensional cluster analysis of 7 BRCA1-associated and 6 BRCA2-associated breast tumors. Two dimensional presentation of transcript ratios for 13 tumors. The top 150 significant genes differentially expressed between the two tumor groups from SAM Moderated t-test are shown. Each column represents a tumor and each row a gene. As shown in the color bar, red indicates up regulation, green down regulation and black no change
###end p 41
###begin p 42
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Unsupervised two dimensional cluster analysis of 7 BRCA1-associated and 6 BRCA2-associated breast tumors. Two dimensional presentation of transcript ratios for 13 tumors. The top 150 significant genes differentially expressed between the two tumor groups from SAM Moderated t-test are shown. Each column represents a tumor and each row a gene. As shown in the color bar, red indicates up regulation, green down regulation and black no change
###end p 42
###begin p 43
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 391 396 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 473 474 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 500 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
BRCA1-associated tumors were characterized by the higher relative expression of 52 of these clones. Using the gene ontology database (NCBI), these genes was predicted to be involved in diverse cellular functions such as proliferation, angiogenesis, cell motility, cell adhesion, transcription and DNA repair. Involvement in the MAPK, Wnt, EGFR and TGFbeta signaling pathways was identified. BRCA1-associated differentially expressed genes included stathmin/oncoprotein 18 (P = 0.0002), osteopontin (P = 0.002) and TGFbeta2 (0.011).
###end p 43
###begin p 44
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF1</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
BRCA2-associated tumors preferentially expressed 98 of the 150 clones. These genes were found to have functions related to transcription, signal transduction, cell proliferation, cell adhesion and extracellular matrix remodeling. Involvement in the MAPK signaling pathway was common. BRCA2-associated cancers were characterized by the higher relative expression of FGF1 (P = 0.003) and FGFR2 (P = 0.004).
###end p 44
###begin title 45
Validation of differentially expressed genes by real time RT-PCR and IHC
###end title 45
###begin p 46
###xml 221 227 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-</italic>
###xml 234 239 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 407 412 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 447 452 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 472 473 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 511 512 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 515 520 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 583 588 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 611 616 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 834 835 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 847 848 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 886 892 880 886 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1000 1005 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1021 1025 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 1169 1174 1163 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1202 1207 1196 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 892 1481 886 1475 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Scatter plots comparing the expression ratios of 6 genes obtained using both cDNA microarrays and RT-PCR in <italic>BRCA1</italic>-associated and <italic>BRCA</italic>2-associated tumors. The log2 expression ratios from RT-PCR (y-axis) and log2 expression ratios from cDNA microarrays (x-axis) for 6 genes from <italic>BRCA1</italic>-associated (red spots) and <italic>BRCA2</italic>-associated (purple spots) tumors are illustrated in the scatter plots. The relative expression ratios for both modalities for each tumor correlate positively i.e., RT-PCR and expression data go in the same direction (up regulated or down regulated) for the two tumor groups</p>
###xml 892 1481 886 1475 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Scatter plots comparing the expression ratios of 6 genes obtained using both cDNA microarrays and RT-PCR in <italic>BRCA1</italic>-associated and <italic>BRCA</italic>2-associated tumors. The log2 expression ratios from RT-PCR (y-axis) and log2 expression ratios from cDNA microarrays (x-axis) for 6 genes from <italic>BRCA1</italic>-associated (red spots) and <italic>BRCA2</italic>-associated (purple spots) tumors are illustrated in the scatter plots. The relative expression ratios for both modalities for each tumor correlate positively i.e., RT-PCR and expression data go in the same direction (up regulated or down regulated) for the two tumor groups</p></caption>
###xml 1481 1481 1475 1475 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2008_87_Fig2_HTML" id="MO2"/>
###xml 886 1481 880 1475 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="47">Scatter plots comparing the expression ratios of 6 genes obtained using both cDNA microarrays and RT-PCR in <italic>BRCA1</italic>-associated and <italic>BRCA</italic>2-associated tumors. The log2 expression ratios from RT-PCR (y-axis) and log2 expression ratios from cDNA microarrays (x-axis) for 6 genes from <italic>BRCA1</italic>-associated (red spots) and <italic>BRCA2</italic>-associated (purple spots) tumors are illustrated in the scatter plots. The relative expression ratios for both modalities for each tumor correlate positively i.e., RT-PCR and expression data go in the same direction (up regulated or down regulated) for the two tumor groups</p></caption><graphic position="anchor" xlink:href="10549_2008_87_Fig2_HTML" id="MO2"/></fig>
To confirm the differences in gene expression, quantitative real-time RT-PCR was performed for several genes including FGF1, FGFR2, stathmin/oncoprotein 18, osteopontin and TGFbeta2. Due to limited amounts of RNA, only 5 BRCA1- and 6 BRCA2-associated tumor RNAs were available for RT-PCR. Similar to the microarray data, the levels of expression of osteopontin and TGFbeta2 were significantly higher in the BRCA1-associated tumors compared to the BRCA2-associated tumors (P = 0.03 and 0.001, respectively, Fig. 2). BRCA2-associated tumors expressed higher levels of FGF1 compared to BRCA1-associated tumors and BRCA1-associated tumors had higher levels of stathmin/oncoprotein 18 compare to BRCA2-associate tumors, similar to the microarray data; but these differences however, did not reach statistical significance at the 5% level (P = 0.76 and P = 0.28 respectively, data not shown).Fig. 2Scatter plots comparing the expression ratios of 6 genes obtained using both cDNA microarrays and RT-PCR in BRCA1-associated and BRCA2-associated tumors. The log2 expression ratios from RT-PCR (y-axis) and log2 expression ratios from cDNA microarrays (x-axis) for 6 genes from BRCA1-associated (red spots) and BRCA2-associated (purple spots) tumors are illustrated in the scatter plots. The relative expression ratios for both modalities for each tumor correlate positively i.e., RT-PCR and expression data go in the same direction (up regulated or down regulated) for the two tumor groups
###end p 46
###begin p 47
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Scatter plots comparing the expression ratios of 6 genes obtained using both cDNA microarrays and RT-PCR in BRCA1-associated and BRCA2-associated tumors. The log2 expression ratios from RT-PCR (y-axis) and log2 expression ratios from cDNA microarrays (x-axis) for 6 genes from BRCA1-associated (red spots) and BRCA2-associated (purple spots) tumors are illustrated in the scatter plots. The relative expression ratios for both modalities for each tumor correlate positively i.e., RT-PCR and expression data go in the same direction (up regulated or down regulated) for the two tumor groups
###end p 47
###begin p 48
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 517 523 517 523 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2-</italic>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 630 631 630 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 638 639 638 639 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 662 667 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 769 770 769 770 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 838 839 838 839 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 865 866 865 866 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 873 874 873 874 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 895 900 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 916 921 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 979 980 979 980 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1062 1063 1062 1063 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 523 1076 523 1076 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Immunohistochemical and ISH studies on representative <italic>BRCA2-</italic>associated and <italic>BRCA1</italic>-associated tumors. Tumor (<bold>a</bold>) and (<bold>b</bold>) are a representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumor stained for FGFR2. The cytoplasmic stain is positive in tumor (<bold>a</bold>) as evidenced by the intense brown staining and negative in tumor (<bold>b</bold>). Tumors represented in (<bold>c</bold>) and (<bold>d</bold>) are representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumors following ISH for Jagged1 mRNA. Tumor (<bold>c</bold>) is negative, with a vessel acting as a positive internal control whereas tumor (<bold>d</bold>) is positive</p>
###xml 523 1076 523 1076 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">Immunohistochemical and ISH studies on representative <italic>BRCA2-</italic>associated and <italic>BRCA1</italic>-associated tumors. Tumor (<bold>a</bold>) and (<bold>b</bold>) are a representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumor stained for FGFR2. The cytoplasmic stain is positive in tumor (<bold>a</bold>) as evidenced by the intense brown staining and negative in tumor (<bold>b</bold>). Tumors represented in (<bold>c</bold>) and (<bold>d</bold>) are representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumors following ISH for Jagged1 mRNA. Tumor (<bold>c</bold>) is negative, with a vessel acting as a positive internal control whereas tumor (<bold>d</bold>) is positive</p></caption>
###xml 1076 1076 1076 1076 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2008_87_Fig3_HTML" id="MO3"/>
###xml 517 1076 517 1076 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="49">Immunohistochemical and ISH studies on representative <italic>BRCA2-</italic>associated and <italic>BRCA1</italic>-associated tumors. Tumor (<bold>a</bold>) and (<bold>b</bold>) are a representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumor stained for FGFR2. The cytoplasmic stain is positive in tumor (<bold>a</bold>) as evidenced by the intense brown staining and negative in tumor (<bold>b</bold>). Tumors represented in (<bold>c</bold>) and (<bold>d</bold>) are representative <italic>BRCA2</italic>-associated and <italic>BRCA1</italic>-associated tumors following ISH for Jagged1 mRNA. Tumor (<bold>c</bold>) is negative, with a vessel acting as a positive internal control whereas tumor (<bold>d</bold>) is positive</p></caption><graphic position="anchor" xlink:href="10549_2008_87_Fig3_HTML" id="MO3"/></fig>
Because the levels of FGFR2 were too low to quantitate reliably in the tumors using real time RT-PCR we used immunohistochemistry (IHC) to determine the level of expression of FGFR2 in an independent set of tumors. Tissue microarrays were constructed from FFPE tumors from 64 BRCA2 carriers, 58 BRCA1 carriers and 242 individuals without BRCA1 or BRCA2 mutations. A total of 19 out of 64 (30%) BRCA2-associated tumors stained positive for FGFR2 compared to 3 of 50 (6%) of BRCA1-associated tumors (P = 0.004, Fig. 3).Fig. 3Immunohistochemical and ISH studies on representative BRCA2-associated and BRCA1-associated tumors. Tumor (a) and (b) are a representative BRCA2-associated and BRCA1-associated tumor stained for FGFR2. The cytoplasmic stain is positive in tumor (a) as evidenced by the intense brown staining and negative in tumor (b). Tumors represented in (c) and (d) are representative BRCA2-associated and BRCA1-associated tumors following ISH for Jagged1 mRNA. Tumor (c) is negative, with a vessel acting as a positive internal control whereas tumor (d) is positive
###end p 48
###begin p 49
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2-</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 107 108 107 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 115 116 115 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 246 247 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 315 316 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 342 343 342 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 350 351 350 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 456 457 456 457 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 539 540 539 540 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
Immunohistochemical and ISH studies on representative BRCA2-associated and BRCA1-associated tumors. Tumor (a) and (b) are a representative BRCA2-associated and BRCA1-associated tumor stained for FGFR2. The cytoplasmic stain is positive in tumor (a) as evidenced by the intense brown staining and negative in tumor (b). Tumors represented in (c) and (d) are representative BRCA2-associated and BRCA1-associated tumors following ISH for Jagged1 mRNA. Tumor (c) is negative, with a vessel acting as a positive internal control whereas tumor (d) is positive
###end p 49
###begin p 50
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 676 677 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 820 821 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 973 974 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1001 1002 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1030 1031 1030 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1102 1103 1102 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1118 1119 1118 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1121 1128 1121 1128 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1209 1210 1209 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1128 1217 1128 1217 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Association between FGFR2 expression and other IHC markers in all breast tumors (<italic>n</italic>&#160;=&#160;248)</p>
###xml 1128 1217 1128 1217 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Association between FGFR2 expression and other IHC markers in all breast tumors (<italic>n</italic>&#160;=&#160;248)</p></caption>
###xml 1217 1229 1217 1229 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Other marker</th>
###xml 1229 1234 1229 1234 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">FGFR2</th>
###xml 1217 1234 1217 1234 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Other marker</th><th align="left" colspan="5">FGFR2</th></tr>
###xml 1234 1242 1234 1242 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Positive</th>
###xml 1242 1250 1242 1250 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Negative</th>
###xml 1250 1251 1250 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1250 1259 1250 1259 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic>-value**</th>
###xml 1234 1259 1234 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Positive</th><th align="left" colspan="2">Negative</th><th align="left"><italic>P</italic>-value**</th></tr>
###xml 1259 1260 1259 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1259 1261 1259 1261 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic>*</th>
###xml 1261 1262 1261 1262 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">%</th>
###xml 1262 1263 1262 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1262 1263 1262 1263 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic></th>
###xml 1263 1264 1263 1264 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">%</th>
###xml 1264 1264 1264 1264 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1259 1264 1259 1264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>n</italic>*</th><th align="left">%</th><th align="left"><italic>n</italic></th><th align="left">%</th><th align="left"/></tr>
###xml 1217 1264 1217 1264 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Other marker</th><th align="left" colspan="5">FGFR2</th></tr><tr><th align="left" colspan="2">Positive</th><th align="left" colspan="2">Negative</th><th align="left"><italic>P</italic>-value**</th></tr><tr><th align="left"><italic>n</italic>*</th><th align="left">%</th><th align="left"><italic>n</italic></th><th align="left">%</th><th align="left"/></tr></thead>
###xml 1264 1266 1264 1266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">ER</td>
###xml 1264 1266 1264 1266 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">ER</td></tr>
###xml 1266 1278 1266 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1278 1280 1278 1280 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 1280 1284 1280 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">73.3</td>
###xml 1284 1287 1284 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">102</td>
###xml 1287 1291 1287 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50.3</td>
###xml 1291 1297 1291 1297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">0.0049</bold>
###xml 1291 1297 1291 1297 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><bold>0.0049</bold></td>
###xml 1266 1297 1266 1297 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">33</td><td char="." align="char">73.3</td><td char="." align="char">102</td><td char="." align="char">50.3</td><td char="." align="char"><bold>0.0049</bold></td></tr>
###xml 1297 1310 1297 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1310 1312 1310 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 1312 1316 1312 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26.7</td>
###xml 1316 1319 1316 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">101</td>
###xml 1319 1323 1319 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">49.8</td>
###xml 1323 1323 1323 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1297 1323 1297 1323 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">12</td><td char="." align="char">26.7</td><td char="." align="char">101</td><td char="." align="char">49.8</td><td char="." align="char"/></tr>
###xml 1323 1325 1323 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">PR</td>
###xml 1323 1325 1323 1325 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">PR</td></tr>
###xml 1325 1337 1325 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1337 1339 1337 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1339 1343 1339 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63.8</td>
###xml 1343 1345 1343 1345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">88</td>
###xml 1345 1349 1345 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43.4</td>
###xml 1349 1355 1349 1355 <bold xmlns:xlink="http://www.w3.org/1999/xlink">0.0113</bold>
###xml 1349 1355 1349 1355 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><bold>0.0113</bold></td>
###xml 1325 1355 1325 1355 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">30</td><td char="." align="char">63.8</td><td char="." align="char">88</td><td char="." align="char">43.4</td><td char="." align="char"><bold>0.0113</bold></td></tr>
###xml 1355 1368 1355 1368 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1368 1370 1368 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1370 1374 1370 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.2</td>
###xml 1374 1377 1374 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">115</td>
###xml 1377 1381 1377 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">56.7</td>
###xml 1381 1381 1381 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1355 1381 1355 1381 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">17</td><td char="." align="char">36.2</td><td char="." align="char">115</td><td char="." align="char">56.7</td><td char="." align="char"/></tr>
###xml 1381 1385 1381 1385 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">Her2</td>
###xml 1381 1385 1381 1385 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">Her2</td></tr>
###xml 1385 1397 1385 1397 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1397 1398 1397 1398 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1398 1402 1398 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.6</td>
###xml 1402 1404 1402 1404 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1404 1407 1404 1407 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.9</td>
###xml 1407 1413 1407 1413 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.7936</td>
###xml 1385 1413 1385 1413 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">5</td><td char="." align="char">10.6</td><td char="." align="char">20</td><td char="." align="char">9.9</td><td char="." align="char">0.7936</td></tr>
###xml 1413 1426 1413 1426 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1426 1428 1426 1428 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 1428 1432 1428 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">89.4</td>
###xml 1432 1435 1432 1435 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">182</td>
###xml 1435 1439 1435 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90.1</td>
###xml 1439 1439 1439 1439 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1413 1439 1413 1439 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">42</td><td char="." align="char">89.4</td><td char="." align="char">182</td><td char="." align="char">90.1</td><td char="." align="char"/></tr>
###xml 1439 1442 1439 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">p27</td>
###xml 1439 1442 1439 1442 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">p27</td></tr>
###xml 1442 1454 1442 1454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1454 1456 1454 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 1456 1460 1456 1460 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86.2</td>
###xml 1460 1463 1460 1463 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">110</td>
###xml 1463 1467 1463 1467 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63.2</td>
###xml 1467 1473 1467 1473 <bold xmlns:xlink="http://www.w3.org/1999/xlink">0.0152</bold>
###xml 1467 1473 1467 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><bold>0.0152</bold></td>
###xml 1442 1473 1442 1473 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">25</td><td char="." align="char">86.2</td><td char="." align="char">110</td><td char="." align="char">63.2</td><td char="." align="char"><bold>0.0152</bold></td></tr>
###xml 1473 1486 1473 1486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1486 1487 1486 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1487 1491 1487 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.8</td>
###xml 1491 1493 1491 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">64</td>
###xml 1493 1497 1493 1497 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.8</td>
###xml 1497 1497 1497 1497 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1473 1497 1473 1497 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">4</td><td char="." align="char">13.8</td><td char="." align="char">64</td><td char="." align="char">36.8</td><td char="." align="char"/></tr>
###xml 1497 1500 1497 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">p53</td>
###xml 1497 1500 1497 1500 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">p53</td></tr>
###xml 1500 1512 1500 1512 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1512 1514 1512 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1514 1518 1514 1518 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27.7</td>
###xml 1518 1520 1518 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">77</td>
###xml 1520 1524 1520 1524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38.9</td>
###xml 1524 1530 1524 1530 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1511</td>
###xml 1500 1530 1500 1530 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">13</td><td char="." align="char">27.7</td><td char="." align="char">77</td><td char="." align="char">38.9</td><td char="." align="char">0.1511</td></tr>
###xml 1530 1543 1530 1543 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1543 1545 1543 1545 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">34</td>
###xml 1545 1549 1545 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">72.3</td>
###xml 1549 1552 1549 1552 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">121</td>
###xml 1552 1556 1552 1556 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61.1</td>
###xml 1556 1556 1556 1556 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1530 1556 1530 1556 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">34</td><td char="." align="char">72.3</td><td char="." align="char">121</td><td char="." align="char">61.1</td><td char="." align="char"/></tr>
###xml 1556 1561 1556 1561 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">CK818</td>
###xml 1556 1561 1556 1561 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">CK818</td></tr>
###xml 1561 1573 1561 1573 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1573 1575 1573 1575 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">44</td>
###xml 1575 1579 1575 1579 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">97.8</td>
###xml 1579 1582 1579 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">172</td>
###xml 1582 1586 1582 1586 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">85.2</td>
###xml 1586 1592 1586 1592 <bold xmlns:xlink="http://www.w3.org/1999/xlink">0.0207</bold>
###xml 1586 1592 1586 1592 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><bold>0.0207</bold></td>
###xml 1561 1592 1561 1592 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">44</td><td char="." align="char">97.8</td><td char="." align="char">172</td><td char="." align="char">85.2</td><td char="." align="char"><bold>0.0207</bold></td></tr>
###xml 1592 1605 1592 1605 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1605 1606 1605 1606 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1606 1609 1606 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.2</td>
###xml 1609 1611 1609 1611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1611 1615 1611 1615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.9</td>
###xml 1615 1615 1615 1615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1592 1615 1592 1615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">1</td><td char="." align="char">2.2</td><td char="." align="char">30</td><td char="." align="char">14.9</td><td char="." align="char"/></tr>
###xml 1615 1618 1615 1618 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">CK5</td>
###xml 1615 1618 1615 1618 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">CK5</td></tr>
###xml 1618 1630 1618 1630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1630 1631 1630 1631 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1631 1635 1631 1635 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19.2</td>
###xml 1635 1637 1635 1637 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65</td>
###xml 1637 1641 1637 1641 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">32.0</td>
###xml 1641 1647 1641 1647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0815</td>
###xml 1618 1647 1618 1647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">9</td><td char="." align="char">19.2</td><td char="." align="char">65</td><td char="." align="char">32.0</td><td char="." align="char">0.0815</td></tr>
###xml 1647 1660 1647 1660 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1660 1662 1660 1662 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 1662 1666 1662 1666 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">80.9</td>
###xml 1666 1669 1666 1669 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">138</td>
###xml 1669 1673 1669 1673 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">68.0</td>
###xml 1673 1673 1673 1673 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1647 1673 1647 1673 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">38</td><td char="." align="char">80.9</td><td char="." align="char">138</td><td char="." align="char">68.0</td><td char="." align="char"/></tr>
###xml 1673 1681 1673 1681 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">Vimentin</td>
###xml 1673 1681 1673 1681 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">Vimentin</td></tr>
###xml 1681 1693 1681 1693 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Positive</td>
###xml 1693 1694 1693 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1694 1697 1694 1697 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.9</td>
###xml 1697 1699 1697 1699 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36</td>
###xml 1699 1703 1699 1703 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20.3</td>
###xml 1703 1709 1703 1709 <bold xmlns:xlink="http://www.w3.org/1999/xlink">0.0445</bold>
###xml 1703 1709 1703 1709 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><bold>0.0445</bold></td>
###xml 1681 1709 1681 1709 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">2</td><td char="." align="char">5.9</td><td char="." align="char">36</td><td char="." align="char">20.3</td><td char="." align="char"><bold>0.0445</bold></td></tr>
###xml 1709 1722 1709 1722 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Negative </td>
###xml 1722 1724 1722 1724 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">32</td>
###xml 1724 1728 1724 1728 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">94.1</td>
###xml 1728 1731 1728 1731 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">141</td>
###xml 1731 1735 1731 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79.7</td>
###xml 1735 1735 1735 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1709 1735 1709 1735 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">32</td><td char="." align="char">94.1</td><td char="." align="char">141</td><td char="." align="char">79.7</td><td char="." align="char"/></tr>
###xml 1264 1735 1264 1735 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="6">ER</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">33</td><td char="." align="char">73.3</td><td char="." align="char">102</td><td char="." align="char">50.3</td><td char="." align="char"><bold>0.0049</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">12</td><td char="." align="char">26.7</td><td char="." align="char">101</td><td char="." align="char">49.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">PR</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">30</td><td char="." align="char">63.8</td><td char="." align="char">88</td><td char="." align="char">43.4</td><td char="." align="char"><bold>0.0113</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">17</td><td char="." align="char">36.2</td><td char="." align="char">115</td><td char="." align="char">56.7</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Her2</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">5</td><td char="." align="char">10.6</td><td char="." align="char">20</td><td char="." align="char">9.9</td><td char="." align="char">0.7936</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">42</td><td char="." align="char">89.4</td><td char="." align="char">182</td><td char="." align="char">90.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p27</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">25</td><td char="." align="char">86.2</td><td char="." align="char">110</td><td char="." align="char">63.2</td><td char="." align="char"><bold>0.0152</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">4</td><td char="." align="char">13.8</td><td char="." align="char">64</td><td char="." align="char">36.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p53</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">13</td><td char="." align="char">27.7</td><td char="." align="char">77</td><td char="." align="char">38.9</td><td char="." align="char">0.1511</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">34</td><td char="." align="char">72.3</td><td char="." align="char">121</td><td char="." align="char">61.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK818</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">44</td><td char="." align="char">97.8</td><td char="." align="char">172</td><td char="." align="char">85.2</td><td char="." align="char"><bold>0.0207</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">1</td><td char="." align="char">2.2</td><td char="." align="char">30</td><td char="." align="char">14.9</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK5</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">9</td><td char="." align="char">19.2</td><td char="." align="char">65</td><td char="." align="char">32.0</td><td char="." align="char">0.0815</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">38</td><td char="." align="char">80.9</td><td char="." align="char">138</td><td char="." align="char">68.0</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Vimentin</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">2</td><td char="." align="char">5.9</td><td char="." align="char">36</td><td char="." align="char">20.3</td><td char="." align="char"><bold>0.0445</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">32</td><td char="." align="char">94.1</td><td char="." align="char">141</td><td char="." align="char">79.7</td><td char="." align="char"/></tr></tbody>
###xml 1217 1735 1217 1735 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Other marker</th><th align="left" colspan="5">FGFR2</th></tr><tr><th align="left" colspan="2">Positive</th><th align="left" colspan="2">Negative</th><th align="left"><italic>P</italic>-value**</th></tr><tr><th align="left"><italic>n</italic>*</th><th align="left">%</th><th align="left"><italic>n</italic></th><th align="left">%</th><th align="left"/></tr></thead><tbody><tr><td align="left" colspan="6">ER</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">33</td><td char="." align="char">73.3</td><td char="." align="char">102</td><td char="." align="char">50.3</td><td char="." align="char"><bold>0.0049</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">12</td><td char="." align="char">26.7</td><td char="." align="char">101</td><td char="." align="char">49.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">PR</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">30</td><td char="." align="char">63.8</td><td char="." align="char">88</td><td char="." align="char">43.4</td><td char="." align="char"><bold>0.0113</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">17</td><td char="." align="char">36.2</td><td char="." align="char">115</td><td char="." align="char">56.7</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Her2</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">5</td><td char="." align="char">10.6</td><td char="." align="char">20</td><td char="." align="char">9.9</td><td char="." align="char">0.7936</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">42</td><td char="." align="char">89.4</td><td char="." align="char">182</td><td char="." align="char">90.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p27</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">25</td><td char="." align="char">86.2</td><td char="." align="char">110</td><td char="." align="char">63.2</td><td char="." align="char"><bold>0.0152</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">4</td><td char="." align="char">13.8</td><td char="." align="char">64</td><td char="." align="char">36.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p53</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">13</td><td char="." align="char">27.7</td><td char="." align="char">77</td><td char="." align="char">38.9</td><td char="." align="char">0.1511</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">34</td><td char="." align="char">72.3</td><td char="." align="char">121</td><td char="." align="char">61.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK818</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">44</td><td char="." align="char">97.8</td><td char="." align="char">172</td><td char="." align="char">85.2</td><td char="." align="char"><bold>0.0207</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">1</td><td char="." align="char">2.2</td><td char="." align="char">30</td><td char="." align="char">14.9</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK5</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">9</td><td char="." align="char">19.2</td><td char="." align="char">65</td><td char="." align="char">32.0</td><td char="." align="char">0.0815</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">38</td><td char="." align="char">80.9</td><td char="." align="char">138</td><td char="." align="char">68.0</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Vimentin</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">2</td><td char="." align="char">5.9</td><td char="." align="char">36</td><td char="." align="char">20.3</td><td char="." align="char"><bold>0.0445</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">32</td><td char="." align="char">94.1</td><td char="." align="char">141</td><td char="." align="char">79.7</td><td char="." align="char"/></tr></tbody></table>
###xml 1737 1738 1737 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1735 1746 1735 1746 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">*&#160;<italic>n</italic>: number</p>
###xml 1760 1761 1760 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1746 1778 1746 1778 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53">**&#160;Unadjusted <italic>P</italic>-values are given</p>
###xml 1778 1821 1778 1821 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54">Bold values are significant at the 5% level</p>
###xml 1735 1821 1735 1821 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">*&#160;<italic>n</italic>: number</p><p textid="53">**&#160;Unadjusted <italic>P</italic>-values are given</p><p textid="54">Bold values are significant at the 5% level</p></table-wrap-foot>
###xml 1121 1821 1121 1821 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="51">Association between FGFR2 expression and other IHC markers in all breast tumors (<italic>n</italic>&#160;=&#160;248)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Other marker</th><th align="left" colspan="5">FGFR2</th></tr><tr><th align="left" colspan="2">Positive</th><th align="left" colspan="2">Negative</th><th align="left"><italic>P</italic>-value**</th></tr><tr><th align="left"><italic>n</italic>*</th><th align="left">%</th><th align="left"><italic>n</italic></th><th align="left">%</th><th align="left"/></tr></thead><tbody><tr><td align="left" colspan="6">ER</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">33</td><td char="." align="char">73.3</td><td char="." align="char">102</td><td char="." align="char">50.3</td><td char="." align="char"><bold>0.0049</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">12</td><td char="." align="char">26.7</td><td char="." align="char">101</td><td char="." align="char">49.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">PR</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">30</td><td char="." align="char">63.8</td><td char="." align="char">88</td><td char="." align="char">43.4</td><td char="." align="char"><bold>0.0113</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">17</td><td char="." align="char">36.2</td><td char="." align="char">115</td><td char="." align="char">56.7</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Her2</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">5</td><td char="." align="char">10.6</td><td char="." align="char">20</td><td char="." align="char">9.9</td><td char="." align="char">0.7936</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">42</td><td char="." align="char">89.4</td><td char="." align="char">182</td><td char="." align="char">90.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p27</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">25</td><td char="." align="char">86.2</td><td char="." align="char">110</td><td char="." align="char">63.2</td><td char="." align="char"><bold>0.0152</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">4</td><td char="." align="char">13.8</td><td char="." align="char">64</td><td char="." align="char">36.8</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">p53</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">13</td><td char="." align="char">27.7</td><td char="." align="char">77</td><td char="." align="char">38.9</td><td char="." align="char">0.1511</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">34</td><td char="." align="char">72.3</td><td char="." align="char">121</td><td char="." align="char">61.1</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK818</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">44</td><td char="." align="char">97.8</td><td char="." align="char">172</td><td char="." align="char">85.2</td><td char="." align="char"><bold>0.0207</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">1</td><td char="." align="char">2.2</td><td char="." align="char">30</td><td char="." align="char">14.9</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">CK5</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">9</td><td char="." align="char">19.2</td><td char="." align="char">65</td><td char="." align="char">32.0</td><td char="." align="char">0.0815</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">38</td><td char="." align="char">80.9</td><td char="." align="char">138</td><td char="." align="char">68.0</td><td char="." align="char"/></tr><tr><td align="left" colspan="6">Vimentin</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Positive</td><td char="." align="char">2</td><td char="." align="char">5.9</td><td char="." align="char">36</td><td char="." align="char">20.3</td><td char="." align="char"><bold>0.0445</bold></td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Negative </td><td char="." align="char">32</td><td char="." align="char">94.1</td><td char="." align="char">141</td><td char="." align="char">79.7</td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p textid="52">*&#160;<italic>n</italic>: number</p><p textid="53">**&#160;Unadjusted <italic>P</italic>-values are given</p><p textid="54">Bold values are significant at the 5% level</p></table-wrap-foot></table-wrap>
Furthermore, 25 of 151 (17%) breast tumors from non-mutation carriers were positive for FGFR2, yielding statistically significant differences among the three tumor groups (P = 0.0007). Further analysis of all tumor groups suggested that FGFR2 expression was inversely correlated with the basal phenotype (as defined by the absence of ER, PR and HER2 expression and the presence of CK 5 or EGFR expression), with 9 of 65 (13%) basal-like tumors staining positively for FGFR2 expression compared with 36 of 136 (27%) non-basal-like breast cancers (P = 0.2). More specifically, FGFR2 negative tumors were more likely to be ER negative than FGFR2 positive tumors (49.8 vs. 26.7%, P = 0.004, Table 2). Similarly FGFR2 negative tumors were more likely to be negative for the luminal cytokeratin CK8/18 and p27 (14.9 vs. 2.2%, P = 0.02 and 36.8 vs. 13.8%, P = 0.01 respectively, Table 2) and more likely to be positive for the basal cytokeratin CK 5 and vimentin (32.0 vs. 19.2%, P = 0.08 and 20.3 vs. 5.9%, P = 0.04 respectively, Table 2). FGFR2 expression was also positively associated with PR expression (P = 0.01, Table 2).Table 2Association between FGFR2 expression and other IHC markers in all breast tumors (n = 248)Other markerFGFR2PositiveNegativeP-value**n*%n%ER    Positive3373.310250.30.0049    Negative 1226.710149.8PR    Positive3063.88843.40.0113    Negative 1736.211556.7Her2    Positive510.6209.90.7936    Negative 4289.418290.1p27    Positive2586.211063.20.0152    Negative 413.86436.8p53    Positive1327.77738.90.1511    Negative 3472.312161.1CK818    Positive4497.817285.20.0207    Negative 12.23014.9CK5    Positive919.26532.00.0815    Negative 3880.913868.0Vimentin    Positive25.93620.30.0445    Negative 3294.114179.7* n: number** Unadjusted P-values are givenBold values are significant at the 5% level
###end p 50
###begin p 51
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Association between FGFR2 expression and other IHC markers in all breast tumors (n = 248)
###end p 51
###begin p 52
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
* n: number
###end p 52
###begin p 53
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
** Unadjusted P-values are given
###end p 53
###begin p 54
Bold values are significant at the 5% level
###end p 54
###begin title 55
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
BRCA1-associated tumors
###end title 55
###begin p 56
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 204 209 204 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Since BRCA1-associated tumors cluster with basal-like cancers [5, 6, 20], we evaluated whether genes previously found to be more highly expressed in basal-like tumors were differentially expressed in the BRCA1 compared to the BRCA2 groups. Microarray based values of keratin 17, vimentin and caveolin1 tended to be higher in BRCA1-associated tumors; however, the differences in expression of these genes (P = 0.095, 0.067, and 0.233, respectively) did not meet our global selection cut-off.
###end p 56
###begin p 57
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 489 491 489 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 621 626 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 739 740 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
Recently we have found that basal-like tumors tend to exhibit higher expression of Jagged 1 [21], a ligand involved in Notch pathway signaling. The Notch pathway has been shown to regulate a number of processes important in cancer including angiogenesis [22], epithelial to mesenchymal transition, and stem-cell like characteristics [23]. Using RT-PCR we found that the mean expression level of Jagged 1 tended to be elevated in BRCA1-compared to BRCA2-associated tumors (2.07 versus 0.50, P = 0.11). Because only 11 tumors were available for RT-PCR, we examined the expression of Jagged 1 by mRNA ISH on the TMAs. Of 48 BRCA1-associated tumors, 17 (35%) were positive for Jagged1 by ISH compared to 5 of 53 (9%) BRCA2-associated cancers (P = 0.02, Fig. 3).
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
In recent years, gene expression profiling of breast cancers has improved our understanding of the heterogeneity of the disease and generated hypotheses concerning the development and progression of these cancers. Molecular signatures for BRCA1-associated tumors have been delineated, but BRCA2-associated tumors have been less well studied [5, 7]. To elucidate novel genes involved in the development and progression of BRCA2-associated tumors and to distinguish distinct pathways of carcinogenesis in BRCA1 and BRCA2-associated tumors, we compared gene expression microarray patterns in tumors from BRCA1 and BRCA2 carriers.
###end p 59
###begin p 60
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF1</italic>
###xml 709 714 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
We found that FGFR2 and FGF1 were more highly expressed in BRCA2-associated cancers as compared to BRCA1-associated breast cancers, suggesting the presence of an autocrine growth stimulatory loop. FGF1 and FGFR2 belong to a large family of ligands and receptor tyrosine kinases [24]. FGF1 is a mitogen that signals through FGFRs and subsequently activates the MAPK signaling cascade. Overexpression of FGF1 in breast cancer cell lines has been shown to result in increased anchorage independent growth and reduced requirement for estrogen in vitro and to increased tumorigenicity, angiogenesis and metastatic behaviour in vivo [25, 26]. FGF1 is located at 5q31 a region of the genome often subject to loss in BRCA1-associated cancers [27] and basal-like cancers [28].
###end p 60
###begin p 61
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1405 1407 1405 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1409 1411 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1516 1518 1516 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1806 1811 1806 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1919 1920 1919 1920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 2131 2133 2131 2133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 2291 2292 2291 2292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 2294 2295 2294 2295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 943 948 <span type="species:ncbi:9606">human</span>
FGFR2, located at 10q26, encodes at least two receptor isoforms FGFR2-IIIb and FGFR2-IIIc. FGFR2-IIIc is mainly expressed in tissues of mesenchymal origin, whereas FGFR2-IIIb is expressed in the epithelium of many organs including the mammary gland [29, 30]. The FGFRs in general and FGFR2 specifically have roles in embryogenesis, development and carcinogenesis. FGFR2 mRNA is expressed in many carcinoma cell lines [31-33] and in the breast cancer cell lines examined, FGFR2 expression contributes to their invasive phenotype. Similarly, overexpression of the receptor in normal human mammary epithelial (HME) cells leads to their transformation [34]. These properties are attributable to the activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling cascades [34]. Moreover, the gene locus (10q26) is amplified in 2-10% of breast cancers and its expression has been reported in 50-100% of human breast cancers, with high-level expression confined to 4%-12% of cases [35, 36]. It has also been associated with estrogen (ER) and progesterone (PR) receptor expression and improved overall and disease free survival [35]. Moreover in two recent independent genome wide association studies (GWAS) single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 have been causally associated with increased risk of both familial and sporadic breast cancer [37, 38]. Furthermore this susceptibility locus was associated with younger age of onset and bilateral disease [37]. The authors speculate that the SNPs have functional effects and that the association with breast cancer risk is mediated through regulation of FGFR2 expression possibly through interaction with the ER. In our study we have shown that FGFR2 expression is positively associated with the BRCA2 genotype, a tumor group that we have previously shown to be predominantly ER-positive luminal-type tumors [1]. In addition, we found that FGFR2 expression was positively associated with PR expression, a weak prognostic and predictive factor in breast cancer and often regarded as indicative of a functional ER pathway [39]. Conversely, FGFR2 expression was negatively correlated with basal-like breast cancers which are known to be ER negative and to carry an adverse prognosis [5, 6].
###end p 61
###begin p 62
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 456 457 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 1376 1378 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1412 1417 1412 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1453 1454 1453 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1456 1457 1456 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1459 1460 1459 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1198 1203 <span type="species:ncbi:9606">human</span>
Our expression studies support previous reports indicating that BRCA1-associated breast cancers have a basal-like profile [3, 5]. In the BRCA1-associated tumor group, we detected elevated expression of a number of genes, including keratin 17 [5, 6], vimentin, and caveolin 1 [20], that have previously been linked to the basal-like cancers. Our results also suggest that Y-box binding protein-1 is more highly expressed in BRCA1-associated breast cancers (P = 0.001). This protein has recently been demonstrated to transcriptionally induce EGFR which is commonly overexpressed in basal-like cancers [40]. In addition we found that stathmin/oncoprotein 18 and osteopontin were overexpressed in BRCA1-associated tumors relative to BRCA2-associated tumors. The gene for stathmin, located at 1p36, is one of the 70 genes that compose the '70 gene classifier' that predicts poor prognosis in sporadic breast cancer [41] a classifier that correlates closely with the poor performing subgroups from the intrinsic gene set of which basal-like cancers are one [42]. Stathmin is a microtubule depolymerizing protein involved in cell cycle progression and cell motility. It is highly expressed in a number of human malignancies, including breast cancers where it is negatively correlated with ER expression and positively correlated with grade, aneuploidy, proliferation and mutant p53 [43], all characteristic features of BRCA1-associated and basal-like cancers [3, 5, 6].
###end p 62
###begin p 63
###xml 243 245 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 246 248 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 408 410 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 297 302 <span type="species:ncbi:9606">human</span>
Osteopontin, a secreted phosphoprotein, has been shown to interact with a diverse range of factors including integrins, CD44, TGFalpha, EGFR, Met and VEGF leading to the enhancement of cellular migration, invasion, survival and angiogenesis. [44-46]. Osteopontin is expressed in a wide variety of human malignancies and its expression has been reported to be correlated with poor prognosis in breast cancer [47].
###end p 63
###begin p 64
###xml 193 198 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 356 358 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 360 362 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 459 461 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 463 465 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 736 738 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 845 847 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1009 1011 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
Novel results from our expression study include the identification of members of the Notch and TGFbeta signaling pathways, Jagged 1 and TGFbeta2 respectively, as being more highly expressed in BRCA1-associated tumors. Both of these pathways are highly conserved through evolution and play important roles in development, differentiation and tumorigenesis [48, 49]. Moreover, both pathways are known to play a role in mammary stem cell maintenance or renewal [50, 51]. Dontu et al. have shown that Notch signaling can act on mammary stem cells to promote self-renewal, on early progenitor cells to promote proliferation, and on multipotent progenitor cells, facilitating myoepithelial cell lineage specific commitment and proliferation [50]. Furthermore, patients whose breast cancers express Jagged 1 have been found to have a poorer prognosis [17]. Shipitsin and colleagues showed that TGFbeta signaling is upregulated in normal breast stem cells and their malignant counterparts and has prognostic effects [51].
###end p 64
###begin p 65
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 296 301 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 362 367 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
In conclusion, our molecular profiling demonstrates that BRCA1-associated and BRCA2-associated tumors have distinct molecular profiles. Our results confirm the known link between BRCA1-associated tumors and the basal-like signature and highlight a link between the Notch and TGFbeta pathways and BRCA1-associated tumorigenesis. In contrast the data suggest that BRCA2-associated tumors express higher levels of FGFR2 and FGF1, suggesting the existence of an autocrine loop leading to downstream pleiotrophic cellular effects.
###end p 65
###begin title 66
Electronic supplementary material
###end title 66
###begin p 67
(PDF 38 kb)
###end p 67
###begin title 68
Acknowledgements
###end title 68
###begin p 69
###xml 83 120 83 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Grant numbers and sources of support</italic>
The authors thank Dr. Brendan Dickson and Hui Zhang for their technical assistance. Grant numbers and sources of support: This work was supported by the Canadian Breast Cancer Foundation and the National Cancer Institute under RFA #CA-95-003 as part of the Breast Cancer Family Registry (BreastCFR).
###end p 69
###begin p 70
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 70
###begin title 71
References
###end title 71
###begin article-title 72
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays
###end article-title 72
###begin article-title 73
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
###end article-title 73
###begin article-title 74
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
###end article-title 74
###begin article-title 75
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers
###end article-title 75
###begin article-title 76
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 76
###begin article-title 77
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
###end article-title 77
###begin article-title 78
Gene-expression profiles in hereditary breast cancer
###end article-title 78
###begin article-title 79
The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
###end article-title 79
###begin article-title 80
The cooperative familial registry for breast cancer studies: design and first year recruitment rates in Ontario
###end article-title 80
###begin article-title 81
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations
###end article-title 81
###begin article-title 82
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 83
###begin article-title 84
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation
###end article-title 84
###begin article-title 85
###xml 58 63 <span type="species:ncbi:9606">human</span>
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival
###end article-title 85
###begin article-title 86
Prognostic and predictive factors in breast cancer by immunohistochemical analysis
###end article-title 86
###begin article-title 87
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 87
###begin article-title 88
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer
###end article-title 88
###begin article-title 89
Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium
###end article-title 89
###begin article-title 90
The notch ligand, jagged-1, influences the development of primitive hematopoietic precursor cells
###end article-title 90
###begin article-title 91
Mechanisms underlying differential responses to FGF signaling
###end article-title 91
###begin article-title 92
MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands
###end article-title 92
###begin article-title 93
###xml 126 135 <span type="species:ncbi:10090">nude mice</span>
MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice
###end article-title 93
###begin article-title 94
###xml 46 51 <span type="species:ncbi:9606">human</span>
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations
###end article-title 94
###begin article-title 95
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
###end article-title 95
###begin article-title 96
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis
###end article-title 96
###begin article-title 97
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo
###end article-title 97
###begin article-title 98
###xml 61 66 <span type="species:ncbi:9606">human</span>
Expression of keratinocyte growth factor and its receptor in human breast cancer
###end article-title 98
###begin article-title 99
###xml 72 77 <span type="species:ncbi:9606">human</span>
Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer
###end article-title 99
###begin article-title 100
Expression of keratinocyte growth factor and its receptor in colorectal cancer
###end article-title 100
###begin article-title 101
###xml 99 104 <span type="species:ncbi:9606">human</span>
Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells
###end article-title 101
###begin article-title 102
###xml 71 76 <span type="species:ncbi:9606">human</span>
Basic fibroblast growth factor receptors and their prognostic value in human breast cancer
###end article-title 102
###begin article-title 103
###xml 44 49 <span type="species:ncbi:9606">human</span>
Expression of FGF and FGF receptor genes in human breast cancer
###end article-title 103
###begin article-title 104
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 104
###begin article-title 105
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
###end article-title 105
###begin article-title 106
Prognostic factors in breast cancer. College of American pathologists consensus statement 1999
###end article-title 106
###begin article-title 107
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy
###end article-title 107
###begin article-title 108
A gene-expression signature as a predictor of survival in breast cancer
###end article-title 108
###begin article-title 109
Concordance among gene-expression-based predictors for breast cancer
###end article-title 109
###begin article-title 110
###xml 53 58 <span type="species:ncbi:9606">human</span>
Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors
###end article-title 110
###begin article-title 111
Vascular endothelial growth factor and osteopontin in tumor biology
###end article-title 111
###begin article-title 112
###xml 53 58 <span type="species:ncbi:9606">human</span>
Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (met)
###end article-title 112
###begin article-title 113
###xml 33 38 <span type="species:ncbi:9606">human</span>
Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways
###end article-title 113
###begin article-title 114
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer
###end article-title 114
###begin article-title 115
Regulation of differentiation by TGF-beta
###end article-title 115
###begin article-title 116
The two faces of transforming growth factor beta in carcinogenesis
###end article-title 116
###begin article-title 117
###xml 54 59 <span type="species:ncbi:9606">human</span>
Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells
###end article-title 117
###begin article-title 118
Molecular definition of breast tumor heterogeneity
###end article-title 118
###begin p 119
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 119
###begin p 120
The online version of this article (doi:10.1007/s10549-008-0087-1) contains supplementary material, which is available to authorized users.
###end p 120
###begin p 121
An erratum to this article can be found at
###end p 121

